CL2022001999A1 - Anticuerpos contra la integrina alfavbeta8 para su uso en el tratamiento de la enfermedad renal - Google Patents
Anticuerpos contra la integrina alfavbeta8 para su uso en el tratamiento de la enfermedad renalInfo
- Publication number
- CL2022001999A1 CL2022001999A1 CL2022001999A CL2022001999A CL2022001999A1 CL 2022001999 A1 CL2022001999 A1 CL 2022001999A1 CL 2022001999 A CL2022001999 A CL 2022001999A CL 2022001999 A CL2022001999 A CL 2022001999A CL 2022001999 A1 CL2022001999 A1 CL 2022001999A1
- Authority
- CL
- Chile
- Prior art keywords
- integrin
- kidney
- kidney disease
- tissue
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Se proporcionan métodos y composiciones para tratar una enfermedad renal, tal como enfermedad renal crónica (CKD), en los que los métodos y composiciones comprenden anticuerpos o un fragmento de unión al antígeno de estos que se unen de manera específica y selectiva a la integrina alfavbeta8 humana, de la que se descubrió, como se describe, que presenta una expresión muy elevada en células y tejido renales y, en particular, tejido renal enfermo o fibrótico. Los anticuerpos contra la integrina alfavbeta8 divulgados se unen a la integrina alfavbeta8 humana en el riñón y bloquean la activación de TGF-beta a partir de su forma latente en el tejido renal. Los anticuerpos contra alfavbeta8 en los métodos divulgados reducen, atenúan o anulan la fibrosis renal, que está asociada con la actividad de la integrina alfavbeta8 y TGF-beta en el tejido renal. Los anticuerpos y métodos divulgados tratan de manera eficaz la enfermedad renal, en particular, la fibrosis asociada con la enfermedad renal, tal como CKD, en individuos que lo necesiten.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062966258P | 2020-01-27 | 2020-01-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022001999A1 true CL2022001999A1 (es) | 2023-01-27 |
Family
ID=74561850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022001999A CL2022001999A1 (es) | 2020-01-27 | 2022-07-25 | Anticuerpos contra la integrina alfavbeta8 para su uso en el tratamiento de la enfermedad renal |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230112035A1 (es) |
| EP (1) | EP4096785A1 (es) |
| JP (1) | JP2023511686A (es) |
| KR (1) | KR20220132567A (es) |
| CN (1) | CN115151305A (es) |
| AR (1) | AR121193A1 (es) |
| AU (1) | AU2021213403A1 (es) |
| BR (1) | BR112022014633A2 (es) |
| CA (1) | CA3167390A1 (es) |
| CL (1) | CL2022001999A1 (es) |
| CO (1) | CO2022011661A2 (es) |
| CR (1) | CR20220392A (es) |
| EC (1) | ECSP22066085A (es) |
| IL (1) | IL294814A (es) |
| MX (1) | MX2022009165A (es) |
| WO (1) | WO2021151889A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024056668A1 (en) | 2022-09-12 | 2024-03-21 | Institut National de la Santé et de la Recherche Médicale | New anti-itgb8 antibodies and its uses thereof |
| US20240327522A1 (en) * | 2023-03-31 | 2024-10-03 | Genentech, Inc. | Anti-alpha v beta 8 integrin antibodies and methods of use |
| CN117143241B (zh) * | 2023-10-26 | 2024-02-23 | 迈威(上海)生物科技股份有限公司 | 与人整合素蛋白itgav/itgb8特异性结合的单克隆抗体 |
| CN117126282B (zh) * | 2023-10-26 | 2024-01-12 | 迈威(上海)生物科技股份有限公司 | 抗体及其在制备阻断αvβ8与Latent TGF-β的结合的药物中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| CN102834412B (zh) * | 2010-02-18 | 2016-01-20 | 加利福尼亚大学董事会 | 整合素αVβ8中和抗体 |
| MX350335B (es) | 2011-08-17 | 2017-09-04 | Univ California | Anticuerpos que enlazan alfa-v beta-8 integrina. |
| PT3157561T (pt) | 2014-06-17 | 2020-03-25 | Univ California | Anticorpos contra alfa-v beta-8 melhorados |
| CN110891605A (zh) * | 2017-06-07 | 2020-03-17 | 希沃尔拜克治疗公司 | 免疫调节化合物的抗体缀合物及其用途 |
-
2021
- 2021-01-26 IL IL294814A patent/IL294814A/en unknown
- 2021-01-26 CR CR20220392A patent/CR20220392A/es unknown
- 2021-01-26 KR KR1020227028722A patent/KR20220132567A/ko active Search and Examination
- 2021-01-26 JP JP2022545136A patent/JP2023511686A/ja active Pending
- 2021-01-26 CN CN202180010557.1A patent/CN115151305A/zh active Pending
- 2021-01-26 WO PCT/EP2021/051753 patent/WO2021151889A1/en active Application Filing
- 2021-01-26 AU AU2021213403A patent/AU2021213403A1/en active Pending
- 2021-01-26 US US17/759,388 patent/US20230112035A1/en active Pending
- 2021-01-26 BR BR112022014633A patent/BR112022014633A2/pt unknown
- 2021-01-26 EP EP21703839.7A patent/EP4096785A1/en active Pending
- 2021-01-26 CA CA3167390A patent/CA3167390A1/en active Pending
- 2021-01-26 MX MX2022009165A patent/MX2022009165A/es unknown
- 2021-01-27 AR ARP210100199A patent/AR121193A1/es unknown
-
2022
- 2022-07-25 CL CL2022001999A patent/CL2022001999A1/es unknown
- 2022-08-18 CO CONC2022/0011661A patent/CO2022011661A2/es unknown
- 2022-08-23 EC ECSENADI202266085A patent/ECSP22066085A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022014633A2 (pt) | 2022-09-13 |
| TW202140554A (zh) | 2021-11-01 |
| EP4096785A1 (en) | 2022-12-07 |
| CN115151305A (zh) | 2022-10-04 |
| MX2022009165A (es) | 2022-08-16 |
| IL294814A (en) | 2022-09-01 |
| CO2022011661A2 (es) | 2022-08-30 |
| AR121193A1 (es) | 2022-04-27 |
| WO2021151889A1 (en) | 2021-08-05 |
| CA3167390A1 (en) | 2021-08-05 |
| US20230112035A1 (en) | 2023-04-13 |
| ECSP22066085A (es) | 2022-09-30 |
| CR20220392A (es) | 2022-09-07 |
| KR20220132567A (ko) | 2022-09-30 |
| AU2021213403A1 (en) | 2022-09-15 |
| JP2023511686A (ja) | 2023-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022001999A1 (es) | Anticuerpos contra la integrina alfavbeta8 para su uso en el tratamiento de la enfermedad renal | |
| CL2020001513A1 (es) | Agente terapéutico que induce citotoxicidad. (divisional solicitud 201700704) | |
| PA8849001A1 (es) | Anticuerpos de c-met | |
| AR065589A1 (es) | Prediccion de respuesta a un inhibidor her | |
| EA200901211A1 (ru) | Антигены белка с5 и их применение | |
| CO6341486A2 (es) | Tratamiento y profilaxis de amiloidosis | |
| PE20151893A1 (es) | Tratamiento del cancer usando anticuerpos que se unen a grp78 en la superficie celular | |
| UY28287A1 (es) | Combinaciones para el tratamiento de enfermedades que impican proliferación, migración o apoptosis celulares de células de mieloma, o angiogénesis | |
| ECSP15005280A (es) | Agentes de unión de proteína de r-espondina humana (rspo3) y usos de los mismos | |
| AR079944A1 (es) | Anticuerpo neutralizante de la actividad de un anticoagulante | |
| DOP2016000102A (es) | (aza)piridopirazolopirimidinonas e indazolopirimidinonas y su uso | |
| CO2022002573A2 (es) | Anticuerpos contra ilt2 y uso de los mismos | |
| UY37967A (es) | Compuestos y métodos para la reducción de la expresión de snca | |
| BR112022024483A2 (pt) | Métodos para tratar mieloma múltiplo | |
| BR112022004861A2 (pt) | Alvelestat para uso no tratamento de rejeição de transplante, síndrome de bronquiolite obliterante e doença de transplante versus hospedeiro | |
| AR115288A1 (es) | Anticuerpos humanizados contra el psma | |
| ECSP10010716A (es) | Combinaciones farmaceuticas. | |
| EA201591522A1 (ru) | Лечение реакции трансплантат против хозяина у подвергаемых трансплантации пациентов | |
| EA202091112A1 (ru) | Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение | |
| BR112018068625A2 (pt) | métodos de tratamento ou prevenção de doença de enxerto contra hospedeiro | |
| EA202191058A1 (ru) | Антитела против муцина-16 и способы их применения | |
| CO2022011944A2 (es) | Moléculas de unión a antígeno contra alppl2 y/o alpp y usos de las mismas | |
| BR102018006534A8 (pt) | Métodos para melhorar a atividade dos retinoides | |
| EA201990042A1 (ru) | Композиции, содержащие тимолол и противовоспалительное средство | |
| CL2022002078A1 (es) | Anticuerpos contra klk5 |